Payment overview · 2025
General Payments
$150,110.30
150 reported records · 13 companies
Healthcare provider profile · identity verified
Carl Joshua Danzig, M.D.
Allopathic & Osteopathic Physicians|Ophthalmology · BONITA SPRINGS, FL · NPI 1619137320
Verified facts
What the public records show
CMS Open Payments records show Carl Joshua Danzig, M.D. received $150,110.30 in general payments during 2025 across 150 reported records.
Astellas Pharma US Inc accounted for 61.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eylea, Eylea Hd, Izervay, Ozurdex, Vabysmo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OZURDEX as an associated drug or biological on 5893 records involving 2120 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozurdex by this doctor in 2024.
Astellas Pharma Global Development reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Izervay as an associated drug or biological on 337 records involving 241 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Izervay by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Izervay as an associated drug or biological on 9089 records involving 3720 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Izervay by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vabysmo as an associated drug or biological on 5830 records involving 2353 distinct recipient NPIs. Public Medicare Part D data also shows 452 claims for Vabysmo by this doctor in 2024.
Genentech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Lucentis as an associated drug or biological on 11 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lucentis by this doctor in 2024.
Genentech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vabysmo as an associated drug or biological on 327 records involving 272 distinct recipient NPIs. Public Medicare Part D data also shows 452 claims for Vabysmo by this doctor in 2024.
Regeneron Healthcare Solutions, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EYLEA as an associated drug or biological on 1388 records involving 616 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Eylea by this doctor in 2024.
Regeneron Healthcare Solutions, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EYLEA HD as an associated drug or biological on 10856 records involving 2796 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eylea Hd by this doctor in 2024.
Regeneron Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EYLEA as an associated drug or biological on 298 records involving 184 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Eylea by this doctor in 2024.
Regeneron Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EYLEA HD as an associated drug or biological on 945 records involving 377 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eylea Hd by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $91,955.04 | 61.3% | 61 | 2025 |
| Ocular Therapeutix, Inc. | Unresolved — no canonical attribution shown | $36,074.92 | 24.0% | 46 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $9,196.41 | 6.1% | 11 | 2025 |
| Astellas Pharma Global Development | Unresolved — no canonical attribution shown | $5,155.40 | 3.4% | 5 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $3,343.69 | 2.2% | 6 | 2025 |
| Genentech, Inc. | Unresolved — no canonical attribution shown | $1,708.49 | 1.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $1,227.10 | 0.8% | 3 | 2025 |
| Samsung Bioepis Co., Ltd. | Unresolved — no canonical attribution shown | $712.50 | 0.5% | 1 | 2025 |
| Harrow Eye, LLC | Unresolved — no canonical attribution shown | $342.83 | 0.2% | 4 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $146.02 | 0.1% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $108.93 | 0.1% | 3 | 2025 |
| Regeneron Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $92.73 | 0.1% | 3 | 2025 |
| BIOTISSUE HOLDINGS INC. | Unresolved — no canonical attribution shown | $46.24 | 0.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $78,900.00 | 13 |
| Consulting Fee | $57,347.91 | 49 |
| Travel and Lodging | $9,636.96 | 27 |
| Food and Beverage | $4,225.43 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Izervay Normalized: izervay |
Drug | Astellas Pharma Global Development, Astellas Pharma US Inc | $97,110.44 | 66 | 2025 |
Source payment records
|
|||||
| Vabysmo Normalized: vabysmo |
Drug | Genentech USA, Inc., Genentech, Inc. | $6,980.11 | 8 | 2025 |
Source payment records
|
|||||
| OZURDEX Normalized: ozurdex |
Drug | ABBVIE INC. | $1,227.10 | 3 | 2025 |
Source payment records
|
|||||
| DEXTENZA Normalized: dextenza |
Drug | Ocular Therapeutix, Inc. | $741.59 | 9 | 2025 |
Source payment records
|
|||||
| E301 Normalized: e301 |
Biological | Samsung Bioepis Co., Ltd. | $712.50 | 1 | 2025 |
Source payment records
|
|||||
| IHEEZO Normalized: iheezo |
Drug | Harrow Eye, LLC | $342.83 | 4 | 2025 |
Source payment records
|
|||||
| EYLEA HD Normalized: eylea hd |
Biological | Regeneron Healthcare Solutions, Inc., Regeneron Pharmaceuticals, Inc. | $238.75 | 5 | 2025 |
Source payment records
|
|||||
| YUTIQ Normalized: yutiq |
Drug | ANI Pharmaceuticals, Inc. | $108.93 | 3 | 2025 |
Source payment records
|
|||||
| Syfovre Normalized: syfovre |
Drug | Apellis Pharmaceuticals, Inc. | $92.46 | 3 | 2025 |
Source payment records
|
|||||
| EYLEA Normalized: eylea |
Biological | Regeneron Pharmaceuticals, Inc. | $73.28 | 2 | 2025 |
Source payment records
|
|||||
| Susvimo Normalized: susvimo |
Drug | Genentech USA, Inc. | $12.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EYLEA eylea |
2025 | Eylea | 2024 | 167 | exact normalized | Medicare Part D |
| EYLEA HD eylea hd |
2025 | Eylea Hd | 2024 | 99 | exact normalized | Medicare Part D |
| Izervay izervay |
2025 | Izervay | 2024 | 100 | exact normalized | Medicare Part D |
| OZURDEX ozurdex |
2025 | Ozurdex | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Vabysmo vabysmo |
2025 | Vabysmo | 2024 | 452 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | OZURDEX open payments reported associated product |
CMS Open Payments — General Payments 5893 supporting records · 2120 recipient NPIs · example record 1201352532 |
Ozurdex · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma Global Development Exact reporting entity; no affiliate inference |
2025 | Izervay open payments reported associated product |
CMS Open Payments — General Payments 337 supporting records · 241 recipient NPIs · example record 1234123218 |
Izervay · 2024 Exact normalized brand match · 1 Part D row |
100 | 16 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Izervay open payments reported associated product |
CMS Open Payments — General Payments 9089 supporting records · 3720 recipient NPIs · example record 1238560688 |
Izervay · 2024 Exact normalized brand match · 1 Part D row |
100 | 16 |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Vabysmo open payments reported associated product |
CMS Open Payments — General Payments 5830 supporting records · 2353 recipient NPIs · example record 1211488398 |
Vabysmo · 2024 Exact normalized brand match · 1 Part D row |
452 | 92 |
| Genentech, Inc. Exact reporting entity; no affiliate inference |
2025 | Lucentis open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 8 recipient NPIs · example record 1211493054 |
Lucentis · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Genentech, Inc. Exact reporting entity; no affiliate inference |
2025 | Vabysmo open payments reported associated product |
CMS Open Payments — General Payments 327 supporting records · 272 recipient NPIs · example record 1211488686 |
Vabysmo · 2024 Exact normalized brand match · 1 Part D row |
452 | 92 |
| Regeneron Healthcare Solutions, Inc. Exact reporting entity; no affiliate inference |
2025 | EYLEA open payments reported associated product |
CMS Open Payments — General Payments 1388 supporting records · 616 recipient NPIs · example record 1212855193 |
Eylea · 2024 Exact normalized brand match · 1 Part D row |
167 | 49 |
| Regeneron Healthcare Solutions, Inc. Exact reporting entity; no affiliate inference |
2025 | EYLEA HD open payments reported associated product |
CMS Open Payments — General Payments 10856 supporting records · 2796 recipient NPIs · example record 1212855193 |
Eylea Hd · 2024 Exact normalized brand match · 1 Part D row |
99 | 28 |
| Regeneron Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EYLEA open payments reported associated product |
CMS Open Payments — General Payments 298 supporting records · 184 recipient NPIs · example record 1213234991 |
Eylea · 2024 Exact normalized brand match · 1 Part D row |
167 | 49 |
| Regeneron Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EYLEA HD open payments reported associated product |
CMS Open Payments — General Payments 945 supporting records · 377 recipient NPIs · example record 1213234971 |
Eylea Hd · 2024 Exact normalized brand match · 1 Part D row |
99 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vabysmo | Faricimab-Svoa | 452 | 92 |
| Latanoprost | Latanoprost | 253 | 78 |
| Eylea | Aflibercept | 167 | 49 |
| Brimonidine Tartrate | Brimonidine Tartrate | 116 | 33 |
| Izervay | Avacincaptad Pegol Sodium/Pf | 100 | 16 |
| Eylea Hd | Aflibercept | 99 | 28 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 86 | 31 |
| Prednisolone Acetate | Prednisolone Acetate | 85 | 43 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 75 | 29 |
| Dorzolamide Hcl | Dorzolamide Hcl | 41 | 16 |
| Ofloxacin | Ofloxacin | 37 | 30 |
| Combigan | Brimonidine Tartrate/Timolol | 32 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 32 | suppressed |
| Difluprednate | Difluprednate | 23 | suppressed |
| Prolensa | Bromfenac Sodium | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Lucentis | Ranibizumab | 19 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 17 | 14 |
| Restasis | Cyclosporine | 16 | suppressed |
| Fluorometholone | Fluorometholone | 14 | suppressed |
| Alphagan P | Brimonidine Tartrate | 13 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 12 | suppressed |
| Ozurdex | Dexamethasone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $150,110.30 · 150 records | Astellas Pharma US Inc | DEXTENZA, E301, EYLEA, EYLEA HD, IHEEZO, Izervay, OZURDEX, Susvimo, Syfovre, Vabysmo, YUTIQ | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eylea play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error